2332861
Project Grant
Overview
Grant Description
Sbir Phase I: Development of a DNA-Linked Kinase Assay -The broader impact of this Small Business Innovation Research (SBIR) Phase I project is the development of a highly specific and sensitive kinase assay that can be used as a research tool to discover new therapeutic targets or a clinical diagnostic test.
Kinases are involved in the dysregulation of multiple cellular processes that drive the pathogenesis of various diseases, such as cancers, diabetes, and Alzheimer's disease. Measuring kinase activities in the early stages of various kinase-driven diseases including cancers could improve patient outcomes and reduce healthcare costs.
Herein, kinase activity assays will be developed in an innovative, low-cost, high-sensitivity, and multiplexed format to improve kinase activity detection and quantification for cancer-related kinases. This approach offers a critically needed innovation that could overcome multiple barriers facing existing kinase assays and better arm scientists and clinicians to understand kinase function and for personalized treatment.
The development of this assay has the potential to drive new discoveries and improve clinical care across many disease areas by enabling researchers and clinicians to detect kinase activities precisely. The proposed project addresses the unmet need for sensitive, accurate, and cost-effective methods to quantify kinase activity in disease.
Current kinase assay systems lack key features required for precise measurement of disease-related kinase activities. This Phase I project aims to develop a novel DNA-based kinase assay platform that enables multiplexed quantification of kinase activities with superior sensitivity and specificity compared to existing assays.
DNA-based activity assays offer advantages, including cost-effectiveness, high multiplexing ability, and sensitivity. The assay is estimated to be 10- to 100-fold cheaper than current assays due to the low cost of DNA synthesis and multiplexing capability.
Successful completion of Phase I will demonstrate the feasibility of utilizing this DNA-based approach for measuring kinase activities in cancer cell lysates. Subsequent Phase II studies will validate the assay with clinical samples such as patient blood, urine, and tissues.
Ultimately, this DNA-based kinase assay platform aims to enable highly sensitive kinase activity profiling that is currently unattainable. This will pave the way for assay-guided patient stratification and therapeutic development by overcoming the limitations of current kinase assays.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. - Subawards are not planned for this award.
Kinases are involved in the dysregulation of multiple cellular processes that drive the pathogenesis of various diseases, such as cancers, diabetes, and Alzheimer's disease. Measuring kinase activities in the early stages of various kinase-driven diseases including cancers could improve patient outcomes and reduce healthcare costs.
Herein, kinase activity assays will be developed in an innovative, low-cost, high-sensitivity, and multiplexed format to improve kinase activity detection and quantification for cancer-related kinases. This approach offers a critically needed innovation that could overcome multiple barriers facing existing kinase assays and better arm scientists and clinicians to understand kinase function and for personalized treatment.
The development of this assay has the potential to drive new discoveries and improve clinical care across many disease areas by enabling researchers and clinicians to detect kinase activities precisely. The proposed project addresses the unmet need for sensitive, accurate, and cost-effective methods to quantify kinase activity in disease.
Current kinase assay systems lack key features required for precise measurement of disease-related kinase activities. This Phase I project aims to develop a novel DNA-based kinase assay platform that enables multiplexed quantification of kinase activities with superior sensitivity and specificity compared to existing assays.
DNA-based activity assays offer advantages, including cost-effectiveness, high multiplexing ability, and sensitivity. The assay is estimated to be 10- to 100-fold cheaper than current assays due to the low cost of DNA synthesis and multiplexing capability.
Successful completion of Phase I will demonstrate the feasibility of utilizing this DNA-based approach for measuring kinase activities in cancer cell lysates. Subsequent Phase II studies will validate the assay with clinical samples such as patient blood, urine, and tissues.
Ultimately, this DNA-based kinase assay platform aims to enable highly sensitive kinase activity profiling that is currently unattainable. This will pave the way for assay-guided patient stratification and therapeutic development by overcoming the limitations of current kinase assays.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. - Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
West Lafayette,
Indiana
47906-1152
United States
Geographic Scope
Single Zip Code
Dencoda was awarded
Project Grant 2332861
worth $274,990
from National Science Foundation in May 2024 with work to be completed primarily in West Lafayette Indiana United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I: Development of a DNA-linked Kinase Assay
Abstract
The broader impact of this small business innovation research (SBIR) Phase I project is the development of a highly specific and sensitive kinase assay that can be used as a research tool to discover new therapeutic targets or a clinical diagnostic test. Kinases are involved in the dysregulation of multiple cellular processes that drive the pathogenesis of various diseases, such as cancers, diabetes, and Alzheimer’s disease. Measuring kinase activities in the early stages of various kinase-driven diseases including cancers could improve patient outcomes and reduce healthcare costs. Herein, kinase activity assays will be developed in an innovative, low-cost, high-sensitivity, and multiplexed format to improve kinase activity detection and quantification for cancer-related kinases. This approach offers a critically needed innovation that could overcome multiple barriers facing existing kinase assays and better arm scientists and clinicians to understand kinase function and for personalized treatment. The development of this assay has the potential to drive new discoveries and improve clinical care across many disease areas by enabling researchers and clinicians to detect kinase activities precisely.
The proposed project addresses the unmet need for sensitive, accurate, and cost-effective methods to quantify kinase activity in disease. Current kinase assay systems lack key features required for precise measurement of disease-related kinase activities. This Phase I project aims to develop a novel DNA-based kinase assay platform that enables multiplexed quantification of kinase activities with superior sensitivity and specificity compared to existing assays. DNA-based activity assays offer advantages, including cost-effectiveness, high multiplexing ability, and sensitivity. The assay is estimated to be 10- to 100-fold cheaper than current assays due to the low cost of DNA synthesis and multiplexing capability. Successful completion of Phase I will demonstrate the feasibility of utilizing this DNA-based approach for measuring kinase activities in cancer cell lysates. Subsequent Phase II studies will validate the assay with clinical samples such as patient blood, urine, and tissues. Ultimately, this DNA-based kinase assay platform aims to enable highly sensitive kinase activity profiling that is currently unattainable. This will pave the way for assay-guided patient stratification and therapeutic development by overcoming the limitations of current kinase assays.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BT
Solicitation Number
NSF 23-515
Status
(Complete)
Last Modified 5/6/24
Period of Performance
5/1/24
Start Date
4/30/25
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2332861
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
For-Profit Organization (Other Than Small Business)
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
J1W3J87E5MN4
Awardee CAGE
8D0R0
Performance District
IN-04
Senators
Todd Young
Mike Braun
Mike Braun
Modified: 5/6/24